Evidence map›Paper›PMID 26182912›Full record

ArticleCancer gene therapy2015

IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.

K Andrijauskaite, S Suriano, C A Cloud, M Li, P Kesarwani, L S Stefanik, K M Moxley, M L Salem, E Garrett-Mayer, C M Paulos and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Brief in vitro IL-12 conditioning of CD8Cancer immunology, immunotherapy : CII · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

K AndrijauskaiteDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
S SurianoDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
C A CloudDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
M LiDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
P KesarwaniDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
L S StefanikDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
K M MoxleyLoyola University Chicago, Maywood, IL, USA.
M L SalemImmunology and Biotechnology Division, Faculty of Science, Tanta University, Tanta, Egypt.
E Garrett-MayerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
C M Paulos1] Department of Surgery, Medical University of South Carolina, Charleston, SC, USA [2] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
S Mehrotra1] Department of Surgery, Medical University of South Carolina, Charleston, SC, USA [2] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
J N KochenderferExperimental Transplantation and Immunology Branch , National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
D J Cole1] Department of Surgery, Medical University of South Carolina, Charleston, SC, USA [2] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
M P Rubinstein1] Department of Surgery, Medical University of South Carolina, Charleston, SC, USA [2] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Medical University of South Carolina · USLoyola University Chicago · USNational Institutes of Health · USTanta University · EG

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPYP01CA154778 · NCI · LOYOLA UNIVERSITY CHICAGO · PI NISHIMURA, MICHAEL I. · 2011 to 2015
$15.4M
NCI NIH HHS P01 CA154778NCI NIH HHS P01CA54778-01NCI NIH HHS P30 CA138313NCI NIH HHS P30CA138313NIAID NIH HHS HHSN272201300006C
6 · The paper itself

Abstract

The ability to genetically modify T cells is a critical component to many immunotherapeutic strategies and research studies. However, the success of these approaches is often limited by transduction efficiency. As retroviral vectors require cell division for integration, transduction efficiency is dependent on the appropriate activation and culture conditions for T cells. Naive CD8(+) T cells, which are quiescent, must be first activated to induce cell division to allow genetic modification. To optimize this process, we activated mouse T cells with a panel of different cytokines, including interleukin-2 (IL-2), IL-4, IL-6, IL-7, IL-12, IL-15 and IL-23, known to act on T cells. After activation, cytokines were removed, and activated T cells were retrovirally transduced. We found that IL-12 preconditioning of mouse T cells greatly enhanced transduction efficiency, while preserving function and expansion potential. We also observed a similar transduction-enhancing effect of IL-12 preconditioning on human T cells. These findings provide a simple method to improve the transduction efficiencies of CD8(+) T cells.

Indexed as

Transduction, GeneticAnimalsB-Cell Lymphoma 3 ProteinCD8-Positive T-LymphocytesCells, CulturedGene ExpressionHumansInterleukin-12Mice, Inbred C57BLMoloney murine leukemia virusProto-Oncogene ProteinsTranscription FactorsB-Cell Lymphoma 3 ProteinBCL3 protein, humanBcl3 protein, mouseInterleukin-12Proto-Oncogene ProteinsTranscription Factors

Identifiers

PMID26182912
PMCPMC4807400
OpenAlexW1544477391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.